Date of Award
Doctor of Philosophy (PhD)
Current treatments for type 2 diabetes mellitus (T2DM) and obesity do not reliably achieve long-termweight-loss and up to 50% of patients experience nausea and vomiting. Thus, there is a critical need for obesity medications that provide glycemic control with enhanced weight loss and without sideeffects. We recently reported on the development of EP45, a first in class monomeric peptide drug, which displayed glucoregulation and profound weight loss in rats, and an absence of visceral malaise in shrews, a mammalian model capable of vomiting (unlike rats). By targeting multiple weight-loss and glucoregulatory pathways simultaneously with a single drug, GEP44, we can address multiple coexisting conditions to more efficaciously reduce body weight and blood glucose levels, all devoid of side-effects to improve patient tolerance and quality of life.
Chichura, Kylie Sloane, "Design, synthesis, and characterization of monomeric peptide multiagonists for the mitigation of CNS-associated side effects in the treatment of Type II diabetes and Obesity" (2023). Dissertations - ALL. 1665.